Small molecules

#Enodia Therapeutics #Pfizer #Protein degradation #Sec61 inhibitors #Small molecules

Enodia Therapeutics and Pfizer to develop Sec61-targeting small molecules 

Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, has entered into a research collaboration and license agreement with Pfizer to discover and develop Sec61 inhibitors.   The collaboration aims to accelerate the discovery and advancement of novel small-molecule… Read More

#News

#Carterra #Drug discovery #Lab in the loop #Small molecules

Carterra advances lab-in-the-loop drug discovery  

Carterra, a provider of high-throughput surface plasmon resonance (HT-SPR) platforms for antibody and small molecule drug discovery, has collaborated with AstraZeneca to develop hardware and software aimed at advancing lab-in-the loop drug discovery.   Lab-in-the-loop – the model in which AI systems propose drug candidates, wet-lab experiments generate… Read More

#News

#Contract Research Organisations (CROs) #Drug development #Drug discovery #High throughput screening #Small molecules

Advancing small molecule drug discovery

DDW Editor Reece Armstrong speaks to Dr. Zachary Gurard-Levin, CEO and Founder of Peapod Bio about challenges in small molecule drug discovery and what technologies are advancing this sector.    RA: What are the biggest challenges facing small molecule drug discovery and development?  ZG: The challenge that we… Read More

#Exclusive Content

#Bio-Techne #GMP manufacturing #Small molecules

Bio-Techne expands global GMP manufacturing network 

Bio-Techne has opened a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom. The purpose-built 10,000-square-foot Bristol facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Designed to meet the rigorous standards required for… Read More

#News

Brain physiology
#Drug development #Drug discovery #Neuroscience #Sleep disorders #Small molecules

Why sleep is the next frontier in brain health 

Michelle L. Mellion, MD, Chief Medical Officer at AstronauTx discusses why small molecules that can restore deep, restorative sleep, could be key to cognitive diseases such as Alzheimer’s.   Sleep is the bedrock of good brain health. For a long time, the focus has been on the quantity of sleep. A large body of evidence has… Read More

#Exclusive Content

Structure of a molecule
#Drug discovery #Small molecules #Webinar

Webinar: Shorten timelines for small molecule drug discovery projects

Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects.   The webinar will take place on 10 November, 8am PST / 11am EST / 4PM GMT / 5PM CET. Using its ‘Every Compound… Read More

Webinar date:
Supported by Evotec
#News

Molecules
#Drug discovery #Small molecules #Webinar

Webinar: Reduce small molecule discovery timelines to under two years

Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects.   The webinar will take place on 10 November, 8am PST / 11am EST / 4PM GMT / 5PM CET. Using its ‘Every Compound… Read More

Webinar date:
Supported by Evotec
#News

#Drug discovery #Small molecules #Webinar

Webinar: Reduce small molecule discovery timelines to under two years

Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects.   The webinar will take place on 10 November, 8am PST / 11am EST / 4PM GMT / 5PM CET. Using its ‘Every Compound… Read More

Webinar date:
Supported by Evotec
#News

Neural networks
#Artificial intelligence (AI) #Flagship Pioneering #Small molecules

Flagship Pioneering unveils $50 million AI platform

Biotechnology company Flagship Pioneering has unveiled its generative AI platform Expedition Medicines, backed by $50 million in funding.  Flagship believes Expedition Medicines will push the boundaries in medicine to enable the creation of first-in-class therapies across oncology, immunology and other diseases. The platform can learn the rules… Read More

#Business & Investment #News

Structure of a molecule
#Drug discovery #Small molecules #Webinar

Quality drug candidates in under two years

Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. Using its ‘Every Compound a Candidate (ECC)’ approach, Evotec is aiming to reduce timelines to under two years. This webinar on 10 November 2025 will explore the… Read More

Webinar date:
Supported by Evotec
#News

Structure of a molecule
#Drug discovery #Small molecules #Webinar

Quality drug candidates in under two years

Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. Using its ‘Every Compound a Candidate (ECC)’ approach, Evotec is aiming to reduce timelines to under two years. This webinar will explore the current challenges facing small molecule… Read More

Webinar date:
Supported by Evotec
#Webinars

#Biopharmaceuticals #Generics #Politics #Small molecules #United States

Trump directive aims to cut costs of prescription drugs

US President Trump has signed an executive order designed to lower the cost of prescription drug prices, which includes a win for manufacturers of small molecule drugs.  The order comes one day after the Trump administration instituted a national security report into the pharmaceutical industry, which is… Read More

#Business & Investment #News #Trending News

#Cancer research #Cancer therapeutics #Financing #Small molecules #Vivace Therapeutics

Financing secured for cancer drug targeting the Hippo pathway

Vivace Therapeutics has announced the closing of $35 million Series D financing to support the company’s small molecule cancer therapeutics targeting the Hippo pathway. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Proceeds will support… Read More

#Cancer Research #News

Acute lymphoblastic leukemia
#Bantam Pharmaceutical #Clinical trials #Health Canada #Lymphoma #Small molecules

Trial evaluating treatment for R/R mature B-cell lymphomas

Bantam Pharmaceutical, a company targeting selective modulation of mitochondrial dynamics in cancer, is proceeding with a Phase I clinical trial evaluating BTM-3566 in relapsed/refractory (R/R) mature B-cell lymphomas, based on a recent Clinical Trial Application (CTA) cleared by Health Canada. This regulatory milestone enables Bantam to expand its ongoing clinical… Read More

#Cancer Research #News

#Biopharmaceuticals #Clarivate #Market reporting #Small molecules

Eleven drugs tipped for blockbuster status by 2030

Eleven drugs are projected to achieve blockbuster status or revolutionise treatment paradigms within five years, according to Clarivate’s 2025 Drugs to Watch report.  The drugs address critical challenges in areas such as obesity, oncology, and gene therapy, and are forecast to achieve blockbuster sales by 2030 or… Read More

#Editor's Choice #News #Trends & Analysis